Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) is a clinical stage pharmaceutical and biopharmaceutical company that regularly issues news related to its development of prescription drugs for auto-immune inflammatory and fibroinflammatory diseases. As a medicinal and botanical manufacturing company with a focus on prescription botanical drug products, its updates often center on scientific progress, clinical programs and corporate developments.
News coverage for Devonian frequently highlights advances with its lead candidate Thykamine™, the first pharmaceutical product from its SUPREX™ platform. Releases have described comparative in vitro studies against widely used anti-inflammatory drugs, in vivo work in models of MASH and fibrosis, and Phase II clinical data in ulcerative colitis and atopic dermatitis. The company also reports on patent filings, new potential indications and formulation work, such as development of oral forms for gastrointestinal diseases.
Investors and observers can also expect regular financial and corporate news. Devonian publishes quarterly and annual financial results, including commentary on distribution revenues generated by its Altius commercialization subsidiary and on how those revenues support Thykamine™ development. Other announcements cover private placements, stock option grants, changes in officers and directors, shareholder meeting results, option and rights plans, and matters related to financial reporting and exchange approvals.
Because Devonian operates at the intersection of clinical-stage drug development and pharmaceutical distribution in Canada, its news flow combines R&D milestones, regulatory and intellectual property updates, and capital markets activity. Following the DVHGF news stream can help readers track the evolution of its botanical-based pipeline, the status of distribution agreements managed through Altius, and key corporate decisions that shape the company’s long-term strategy.
Devonian Health Group (OTCQB: DVHGF) reported fourth-quarter and fiscal 2025 results for the year ended July 31, 2025. Key metrics: Q4 distribution revenue $1.3M (down 87% YoY), FY distribution revenue $23.6M (up 22% YoY), Q4 net loss $0.375M ($0.003/share), and FY net loss $6.0M ($0.041/share). The FY loss included a $4.6M goodwill impairment and $0.2M IP impairment. R&D spending rose to $2.0M (up 55.8%) to support Thykamine pediatric phase 2/3 and preclinical work. The corporation is debt free after repaying $2.2M and held $7.0M cash at July 31, 2025. Pierre Labbé was appointed to the board.
Devonian Health Group (OTCQB: DVHGF), a clinical-stage biopharmaceutical company, provided updates on multiple fronts. The company reported significant progress with its flagship drug Thykamine™, validating batch-to-batch consistency through advanced analytical techniques and advancing pre-clinical programs in MASH and pulmonary fibrosis, with data expected in fall 2025.
The company is developing oral formulations for Thykamine™ and received positive U.S. dermatologist survey results for pediatric atopic dermatitis applications. Additionally, Devonian announced the upcoming termination of its Pantoprazole Magnesium distribution agreement in April 2026, which represented 10.6% of FY2024 revenues and 4.2% of revenue for the nine months ended April 2025.
The company also corrected details of its recent private placement, noting total gross proceeds of $2.36 million through the issuance of 15.75 million units at $0.15 per unit, each including one share and one warrant exercisable at $0.20 for 24 months.
Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory disease solutions, has completed a non-brokered private placement raising $2.27 million in gross proceeds. The offering consisted of 15,153,332 units priced at $0.15 per unit, with each unit comprising one subordinate voting share and one warrant.
Each warrant allows holders to purchase one share at $0.20 within a 24-month period. The funds will support working capital needs, corporate overhead, and R&D activities. The securities have a four-month restricted hold period ending December 8, 2025.
Devonian Health Group (OTCQB:DVHGF) reported its Q3 2025 financial results, with revenue increasing 36% year-over-year to $7.36 million. The company recorded a net loss of $0.032 per share, primarily due to a $4.84 million non-cash impairment loss related to the expiration of their DEXLANSOPRAZOLE distribution agreement.
The quarter saw significant management changes with Dr. Andre Boulet appointed as CEO and Luc Gregoire as Executive Vice-President Strategy. The company completed preclinical studies for Thykamine™, exploring new applications in inflammatory diseases, including MASH and fibrosis.
Devonian Health Group has successfully achieved reinstatement of its common shares trading on the TSX Venture Exchange (TSXV), effective April 30, 2025. This development follows the resolution of a temporary trading suspension.
Key developments:
- The Autorité des marchés financiers (AMF) issued a Failure-to-File Cease Trade Order on April 7, 2025
- The suspension was due to delayed filing of required interim financial documents for the quarter ending January 31, 2025
- Company submitted the required filings on April 15, 2025
- AMF revoked the cease trade order on April 16, 2025
The required submissions included quarterly financial statements, management's discussion and analysis, and related documentation. Trading will resume under the symbols GSD on TSXV and DVHGF on OTCQB. The company has expressed gratitude to shareholders for their patience and reinforced its dedication to maintaining high compliance standards.
Devonian Health Group (OTCQB: DVHGF) reported strong Q2 2025 financial results with revenue soaring 275% year-over-year to $8.28 million, primarily driven by DEXLANSOPRAZOLE distribution agreement. The company posted a net loss of $0.001 per share, improving from $0.01 loss per share in the previous year.
The company's cash position stood at $8.4 million with zero debt, down from $9.9 million at fiscal year start. Notable achievements include Thykamine™'s superior performance in anti-inflammatory studies versus corticosteroids, positive results in MASH mouse model studies, and new provisional patent applications for Thykamine™ in metabolic dysfunction-associated steatohepatitis and as an anti-fibrotic agent.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has received a failure to file cease trade order (FFCTO) from the Autorité des Marchés Financiers (AMF) due to delayed filing of required interim financial documents for the period ended January 31, 2025.
The FFCTO prohibits all trading of company securities in Canada, including trades through the TSX Venture Exchange. The required documents include interim financial statements, management's discussion and analysis, and related filings that were due by April 1, 2025.
Trading suspension became effective April 8, 2025. The company continues normal business operations and will seek FFCTO revocation once the required filings are submitted. Trading reinstatement requires both FFCTO revocation and Exchange approval following a compliance review.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has announced a delay in filing its Q2 2025 financial statements and MD&A beyond the April 1, 2025 deadline. The delay stems from recently discovered errors in previous financial statements that require amendments.
The company identified two key issues in its FY2024 statements:
- An unrecorded current tax expense and liability of $782,273
- An over-accrual of expenses amounting to $245,000
Additionally, selling expenses were incorrectly applied against revenues instead of being charged to administrative expenses, requiring reclassifications that will increase reported Distribution Revenues and Administrative Expenses by $1,245,477 and $271,754 for FY2024 and FY2023, respectively. The company expects to file both amended previous statements and current period financials within April 2025.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF), a clinical stage focused on inflammatory disease solutions, held its annual general meeting on March 20, 2025. Shareholders approved several key proposals:
- Election of eight directors including André P. Boulet and Dennis Turpin
- Appointment of MNP LLP as independent auditor for fiscal year ending July 31, 2025
- Amendment to the Option Plan to increase shares reserved for issuance to 20% of outstanding shares
- Renewal of the restricted share unit Rights Plan
- Approval of share consolidation up to 70:1 ratio to potentially broaden investor pool and meet minimum trading requirements for potential U.S. stock exchange listing